These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 38411592)

  • 1. Precision care in the treatment of pediatric asthma.
    Mahmood L; Keskin S; Jefferson AA
    Curr Opin Pediatr; 2024 Jun; 36(3):304-309. PubMed ID: 38411592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological treatments in childhood asthma.
    Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
    Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
    Sabbe M; Schleich F; Janssens P; Louis R
    J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
    Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
    Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
    Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
    J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.
    van Dijk YE; Rutjes NW; Golebski K; Şahin H; Hashimoto S; Maitland-van der Zee AH; Vijverberg SJH
    Paediatr Drugs; 2023 Nov; 25(6):677-693. PubMed ID: 37658954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
    Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
    J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of biologics in asthma endotypes.
    Wangberg H; Woessner K
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
    Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
    BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].
    Ito A; Miyoshi S; Toyota H; Suzuki Y; Uehara Y; Hattori S; Takeshita Y; Sakasegawa H; Kuramochi M; Kobayashi K; Sugimoto N; Nagase H
    Arerugi; 2022; 71(3):210-220. PubMed ID: 35569943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asthma Management in Adults.
    Busse WW; Castro M; Casale TB
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):21-33. PubMed ID: 36283607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics in the treatment of asthma in children and adolescents.
    Bacharier LB; Jackson DJ
    J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 15. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma.
    Chan R; Stewart K; Misirovs R; Lipworth BJ
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1497-1505. PubMed ID: 35131510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe asthma: what is new in the new millennium.
    Ntontsi P; Samitas K; Zervas E; Gaga M
    Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.